In this study, we have demonstrated that abundant fibrin–fibronectin complexes in the ECM of micrometastatic tumours facilitate the binding of a sufficient amount of a small molecular, targeted MRI contrast agent, CREKA-Tris(Gd-DOTA)3, to generate robust enhancement for effective molecular MRI of micrometastasis11, 46. Here, FN1 is linked to neoplasm.